SOPHARMA AD: Sales revenues for November 2023

2023-12-20 12:58

publikacja
2023-12-20 12:58

Spis treści:

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
Sales_Revenues_November_2023_espi.pdf (REPORT)

POLISH FINANCIAL SUPERVISION AUTHORITY
		UNI - EN REPORT No		244	/	2023
Date of issue:	2023-12-20
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for November 2023
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, December 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that for the month of November 2023, the Company realized a decrease in sales of 20% compared to the same month of the previous year, incl. 11% decrease in domestic sales and 26% decrease in export sales. For the eleven months from the beginning of 2023, sales increased by a total of 14%, incl. a 3% increase in domestic sales and a 21% increase in export sales.
Annexes
File			Description
Sales_Revenues_November_2023_espi.pdfSales_Revenues_November_2023_espi.pdf			Sales revenues for November 2023

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification
of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date	Name	Position / Function	Signature
2023-12-20	Ognian Donev	Executive Director

Ważne linki